Egis Pharmaceuticals Signs an Exclusive Distribution Agreement with Mundipharma for Pelmeg (biosimilar, pegfilgrastim) in Central and Eastern Europe

Egis Pharmaceuticals Signs an Exclusive Distribution Agreement with Mundipharma for Pelmeg (pegfilgrastim, biosimilar) in Central and Eastern Europe

Shots:

  • Egis Pharmaceuticals acquires exclusive distribution rights of Pelmeg (pegfilgrastim, biosimilar) from Mundipharma to launch the product in four CEE markets i.e. Hungary, Romania, including Latvia and Lithuania 
  • Pelmeg is the fourth biosimilar commercialized by Mundipharma, originally developed by Cinfa Biotech. In 2018, Mundipharma acquired Cinfa Biotech for the expansion of its footprints in biosimilars
  • Pelmeg is a pegylated version of G-CSF subcutaneously delivered biosimilar targeted to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic CT for malignancy and is also approved by EU in Nov 2018

Click here to read full press release/ article | Ref: Egis Pharmaceuticals | Image: Chicago Tribune